Omega-3 Dietary Supplements in Schizophrenia
This trial is active, not recruiting.
|Conditions||schizophrenia, schizophreniform disorder, schizoaffective disorder, bipolar i|
|Treatments||risperidone, omega-3 capsules, amber 50/50 soybean/corn placebo|
|Collaborator||National Institute of Mental Health (NIMH)|
|Start date||May 2013|
|End date||June 2016|
|Trial size||58 participants|
|Trial identifier||NCT01786239, 12-308B|
This 16-week placebo-control study looks to investigate whether patients with schizophrenia for two years or less may benefit from omega-3 supplements.
|Endpoint classification||safety/efficacy study|
|Intervention model||single group assignment|
|Masking||double blind (subject, caregiver, investigator, outcomes assessor)|
time frame: 16 weeks
Male or female participants from 15 years up to 40 years old.
Inclusion Criteria: - Current DSM-IV-defined diagnosis of schizophrenia, schizophreniform, schizoaffective disorder, psychosis NOS or Bipolar I as assessed using the Structured Clinical Interview for Axis I DSM-IV Disorders; - Does not DSM-IV criteria for a current substance-induced psychotic disorder, a psychotic disorder due to a general medical condition, delusional disorder, brief psychotic disorder, shared psychotic disorder, or a mood disorder with psychotic features; - current positive symptoms rated more than 4 (moderate) on one of these BPRS items: conceptual disorganization, grandiosity, hallucinatory behavior, and unusual thought content; - is in a early phase of illness as defined by having taken antipsychotic medications for a cumulative lifetime period of 2 years or less; - age 15 to 40; - competent and willing to sign informed consent; and - for women, negative pregnancy test and agreement to use a medically accepted birth control method. Exclusion Criteria: - serious neurological or endocrine disorder or any medical condition or treatment known to affect the brain; - any medical condition which requires treatment with a medication with psychotropic effects; - significant risk of suicidal or homicidal behavior; - cognitive or language limitations, or any other factor that would preclude subjects providing informed consent; - medical contraindications to treatment with risperidone (e.g. neuroleptic malignant syndrome with prior risperidone exposure), omega-3 supplements (e.g. bleeding disorder, seafood allergies) or placebo capsules (e.g. allergies to capsule components); - contraindications to MRI imaging (e.g. presence of a pacemaker); - lack of response to a prior adequate trial of risperidone; - taking omega-3 supplements within the past 8 weeks, and - requires treatment with an antidepressant or mood stabilizing medication.
|Official title||Detecting Which Patients With Schizophrenia Will Improve With Omega-3 Treatment|
|Principal investigator||Delbert G Robinson, MD|
|Description||This study looks to investigate whether patients with schizophrenia for 2 years or less may benefit from omega-3 supplements. The main hypothesis to be tested in this study is that white matter integrity assessed with diffusion tensor imaging (DTI) and erythrocyte membrane omega-3 concentration may provide the means for identifying patients most likely to derive clinical benefit from omega-3 supplementation. To test this hypothesis the investigators will enroll 58 patients with recent-onset schizophrenia into a 16-week long randomized double blind placebo-controlled study of risperidone versus risperidone plus omega-3 supplementation. Study assessments after consent will include a baseline MRI and an MRI at the final visit, blood-work, clinical interviews to assess symptoms, and medical assessments for side effects. DTI exams and peripheral omega-3 concentration will be obtained prior to the initiation of treatment and the primary outcome measure will be the total Brief Psychiatric Rating Scale Score. Specific aims are: - To examine the efficacy of omega-3 fatty acids as an adjuvant agent in the treatment of patients with recent-onset schizophrenia. The investigators hypothesize that patients treated with omega-3 fatty acids will demonstrate greater Brief Psychiatric Rating Scale (BPRS) reductions compared to the placebo group. - To identify whether pre-treatment fractional anisotropy (FA) assessed by DTI predicts which patients will derive clinical benefit from omega-3 fatty acids. The investigators hypothesize that patients with lower fractional anisotropy will derive greater clinical benefit from omega-3 fatty acid supplementation. - To identify whether pre-treatment peripheral omega-3 fatty acid concentrations predict which patients will derive clinical benefit from omega-3 fatty acids. The investigators hypothesize that patients with lower peripheral omega-3 fatty acid concentrations will derive greater clinical benefit from omega-3 fatty acid supplementation.|
Call for more information